Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based

  • 0 views
  • 04 May, 2022
  • 1 location
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

participants aged ≥13 and <70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start

  • 0 views
  • 17 Jun, 2022
  • 3 locations
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult

  • 0 views
  • 26 Apr, 2021
  • 16 locations
Emicizumab PUPs and Nuwiq ITI Study

This study prospectively investigates the safety, FVIII immunogenicity, and hemostatic efficacy of prophylactic HEMLIBRA® given with a concomitant low dose recombinant factor VIII (rFVIII) known

  • 0 views
  • 13 Mar, 2022
  • 1 location
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Primary Objective: -To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one

bleeding tendency
antihemophilic factor
aptt
type 3 vwd
coagulation studies
  • 0 views
  • 27 May, 2022
  • 4 locations
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Primary Objective: -To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one

bleeding tendency
antihemophilic factor
aptt
type 3 vwd
coagulation studies
  • 9 views
  • 13 May, 2022
  • 4 locations
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

SPK-8016 is in development for the treatment of patients with inhibitors to FVIII. This Phase 1/2, open-label, non-randomized, dose-finding study is part one of a planned two part study of SPK-8016. Part one will evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with clinically severe hemophilia A …

gene therapy
Factor VIII
hemophilia
immunoglobulins
  • 36 views
  • 23 Mar, 2022
  • 12 locations
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be

antihemophilic factor
severe haemophilia a
coagulation factor
  • 0 views
  • 05 Mar, 2022
  • 1 location
Haemophilia and Bone Loss - PHILEOS Study (PHILEOS)

Haemophilia is a rare bleeding disorder, characterized by factor VIII (HA) or factor IX (HB) deficiency. The absence or the reduction of fVIII or fIX result in impaired thrombin generation and

osteoporosis
bleeding tendency
antihemophilic factor
christmas disease
clot formation
  • 15 views
  • 24 Mar, 2022
  • 15 locations
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Factor VIII (FVIII) is a large plasma glycoprotein that participates in blood coagulation. Loss of circulating FVIII activity due to mutations within the F8 gene results in the X-linked

  • 0 views
  • 05 May, 2022
  • 1 location